J. Scott Andrews

Jun 27, 2024 | alz-journals.onlinelibrary.wiley.com | Clifford R. Jack |J. Scott Andrews |Thomas G Beach |Civin Laboratory

1 BACKGROUND In 2011, the National Institute on Aging and the Alzheimer's Association (NIA-AA) convened three workgroups that published separate recommendations for the diagnosis and evaluation of Alzheimer's disease (AD) in its preclinical, mild cognitive impairment (MCI), and dementia phases.1-4 In 2012, an NIA-AA workgroup published a consensus document on the neuropathologic diagnosis of AD.5, 6 Several years later, the NIA-AA convened a single workgroup to update 2011 recommendations for...

Mar 8, 2024 | onlinelibrary.wiley.com | J. Helen Cross |Arturo Benítez |Jeannine Roth |J. Scott Andrews

Reducing the high clinical symptom burden of LGS could increase quality of life of patients and caregivers LGS is associated with high direct costs due to health care resource use and medications; data on indirect costs are lacking Pharmacoresistance is common, and most individuals with LGS require polytherapy and changes to treatment over time There is an unmet need for treatments that address the nonseizure symptoms of LGS There is a need for a greater understanding of and better...

Feb 7, 2023 | alz-journals.onlinelibrary.wiley.com | Ronald Petersen |Paul Aisen |J. Scott Andrews |Alireza Atri

Abstract Alzheimer's disease (AD) clinical trials are designed and powered to detect the impact of a therapeutic intervention, and there has been considerable discussion on what constitutes a clinically meaningful change in those receiving treatment versus placebo. The pathology of AD is complex, beginning many years before clinical symptoms are detectable, with multiple potential opportunities for therapeutic engagement.